Shire in advanced talks for €32bn takeover
Ireland-based drug-maker Shire is in advanced talks to acquire smaller US rivals Baxalta for about $32bn (€29bn) in cash and stock, excluding debt, according to sources.
The two drug-makers may announce a deal as soon as this week, the source added, with the price being discussed is $46.50 to $48 a share.
Final details of the transaction are still being negotiated and the timing and structure of any offer may change, however.
In July, Baxalta rebuffed an unsolicited $30 billion all-stock bid from Shire that valued the company at $45.23 a share.
The company has been seeking a higher offer that includes cash, people familiar with the matter said last month. If a deal succeeds, the merged business would generate $20bn in annual sales by 2020, Shire has said.